Zenas BioPharma Future Growth
Future criteria checks 0/6
Zenas BioPharma's earnings are forecast to decline at 10.3% per annum while its annual revenue is expected to grow at 78.6% per year. EPS is expected to grow by 52.8% per annum. Return on equity is forecast to be -111.1% in 3 years.
Key information
-10.3%
Earnings growth rate
52.8%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 78.6% |
| Future return on equity | -111.1% |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 45 | -227 | -126 | -57 | 2 |
| 12/31/2025 | N/A | -191 | -169 | -177 | 2 |
| 12/31/2024 | N/A | -145 | -132 | -125 | 2 |
| 9/30/2024 | N/A | -129 | -97 | -97 | N/A |
| 6/30/2024 | 50 | -55 | -34 | -34 | N/A |
| 3/31/2024 | 50 | -46 | -24 | -24 | N/A |
| 12/31/2023 | 50 | -37 | -31 | -31 | N/A |
| 9/30/2023 | 50 | -32 | -33 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZBIO is forecast to have no revenue next year.
High Growth Revenue: ZBIO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZBIO is forecast to be unprofitable in 3 years.